<p>Arcus Biosciences, Inc. (NYSE:RCUS - 獲取免費報告) 的股票在週二交易前出現了跳空上漲。該股票之前收盤價為 21.30 美元，但開盤價為 22.19 美元。Arcus Biosciences 的股票最後交易價格為 22.4330 美元，成交量為 1,292,918 股。</p>
<p>獲取 <strong>Arcus Biosciences</strong> 的提醒：</p>
<h2>分析師設定新的價格目標</h2>
<ul>
<li>從滯後者到領頭羊：小型股正在崛起</li>
</ul>
<p>RCUS 最近成為多份研究報告的主題。Truist Financial 在 12 月 12 日的研究報告中將 Arcus Biosciences 的股票目標價設定為 30.00 美元。Weiss Ratings 在 10 月 8 日的研究報告中重新發布了對 Arcus Biosciences 的 “賣出（d-）” 評級。Wells Fargo &amp; Company 在 10 月 20 日的研究報告中將 Arcus Biosciences 的目標價從 25.00 美元上調至 29.00 美元，並給予該公司 “增持” 評級。摩根士丹利在 1 月 8 日的報告中重申了 “持平” 評級，並將 Arcus Biosciences 的目標價設定為 20.00 美元（從 23.00 美元下調）。最後，高盛集團在週一將 Arcus Biosciences 的評級從 “中性” 上調至 “買入”，並將該公司的目標價從 16.00 美元上調至 28.00 美元。八位股票研究分析師對該股票給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Arcus Biosciences 目前的共識評級為 “適度買入”，平均目標價為 30.00 美元。</p>
<p><strong>獲取我們對 RCUS 的最新股票分析</strong></p>
<h2>Arcus Biosciences 股票上漲 4.8%</h2>
<ul>
<li>MarketBeat 週迴顧 – 7/10 - 7/14</li>
</ul>
<p>該公司的市值為 24.1 億美元，市盈率為-6.49，貝塔值為 0.77。公司的債務與股本比率為 0.22，流動比率為 3.65，速動比率為 3.65。該業務的 50 日移動平均價格為 22.62 美元，200 日移動平均價格為 15.72 美元。</p>
<p>Arcus Biosciences (NYSE:RCUS - 獲取免費報告) 最近於 10 月 28 日發佈了其財報。該公司報告本季度每股收益為 (-1.27) 美元，超出分析師共識預期的 (-1.33) 美元 0.06 美元。Arcus Biosciences 的股本回報率為-68.17%，淨利潤率為-136.40%。該公司本季度的收入為 2600 萬美元，而分析師預期為 1989 萬美元。在去年同期，該公司每股收益為 (-1.00) 美元。Arcus Biosciences 本季度的收入同比下降了 45.8%。平均而言，股票分析師預計 Arcus Biosciences, Inc.在本年度將發佈每股收益為-3.15 美元。</p>
<h2>內部買賣</h2>
<ul>
<li>吉利德通過在 AlloVir 和 Arcus 的股份擴大生物技術足跡</li>
</ul>
<p>在相關消息中，首席執行官 Terry J. Rosen 於 12 月 16 日星期二出售了 28,947 股公司的股票。股票以平均價格 21.88 美元出售，總交易額為 633,360.36 美元。交易完成後，首席執行官直接持有公司 2,220,553 股，價值 48,585,699.64 美元。此次交易使其持股比例減少了 1.29%。該交易在向 SEC 提交的文件中披露，文件可在此鏈接查看。此外，首席運營官 Jennifer Jarrett 於 12 月 16 日星期二出售了 11,225 股公司的股票。股票以平均價格 21.88 美元出售，總交易額為 245,603.00 美元。交易完成後，首席運營官直接持有公司 203,007 股，價值約 4,441,793.16 美元。此次交易使其持股比例減少了 5.24%。該銷售的 SEC 文件提供了更多信息。在過去 90 天內，內部人士共出售了 422,060 股公司股票，價值 9,286,202 美元。內部人士持有公司股票的比例為 9.60%。</p>
<h2>機構資金流入和流出</h2>
<p>機構投資者最近買賣了該股票的股份。GAMMA Investing LLC 在第三季度將其在 Arcus Biosciences 的股份增加了 59.1%。GAMMA Investing LLC 目前擁有 2,748 股公司股票，價值 37,000 美元，此前在上個季度又購買了 1,021 股。SBI Securities Co. Ltd.在第三季度將其在 Arcus Biosciences 的股份增加了 13,547.6%。SBI Securities Co. Ltd.目前擁有 2,866 股公司股票，價值 39,000 美元，此前在上個季度又收購了 2,845 股。Abich Financial Wealth Management LLC 在第三季度購買了 Arcus Biosciences 的新股份，價值 69,000 美元。CWM LLC 在第二季度將其在 Arcus Biosciences 的股份增加了 233.6%。CWM LLC 目前擁有 5,441 股公司股票，價值 44,000 美元，此前在上個季度又收購了 3,810 股。最後，Ameritas Investment Partners Inc.在第二季度將其在 Arcus Biosciences 的股份增加了 34.3%。Ameritas Investment Partners Inc.目前擁有 7,038 股公司股票，價值 57,000 美元，此前在上個季度又收購了 1,796 股。92.89% 的股票目前由對沖基金和其他機構投資者持有。</p>
<h2>Arcus Biosciences 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Arcus Biosciences 是一家臨牀階段的生物製藥公司，專注於新型癌症免疫療法的發現、開發和商業化。該公司的研究平台集中在通過小分子和抗體候選藥物調節腫瘤微環境和免疫檢查點。Arcus 旨在通過靶向腺苷軸和免疫細胞上的抑制受體等途徑增強抗腫瘤免疫反應。</p>
<p>該公司的主要臨牀項目包括 etrumadenant，一種口服給藥的 A2A 腺苷受體拮抗劑，正在與抗 PD-1 療法聯合評估，以及 domvanalimab，一種抗 TIGIT 單克隆抗體。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Arcus Biosciences</li>
<li>埃隆將 SpaceX 上市！$100 的首次公開募股機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地被激活</li>
<li>股票代碼揭曉：獲得 “下一個埃隆·馬斯克” 公司的首次公開募股機會</li>
<li>崩盤已經開始（大多數人還未察覺）</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 $1,000 在 Arcus Biosciences 嗎？</h2>
<p>在您考慮 Arcus Biosciences 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 Arcus Biosciences 並不在名單上。</p>
<p>雖然 Arcus Biosciences 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

RCUS

<p>Arcus Biosciences（紐約證券交易所代碼：RCUS）股價在開盤前從 21.30 美元跳漲至 22.19 美元，最終收於 22.43 美元，成交量為 1,292,918 股。分析師們設定了不同的目標價，Truist Financial 為 30.00 美元，Wells Fargo 為 29.00 美元。該公司報告的季度收入為 2600 萬美元，超出預期，但每股收益為負（1.27 美元）。公司高管進行了股票出售，首席執行官 Terry J. Rosen 出售了價值 633,360 美元的股票。機構投資者最近也增加了對該公司的持股</p>

<p>Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) shares gapped up prior to trading on Tuesday . The stock had previously closed at $21.30, but opened at $22.19. Arcus Biosciences shares last traded at $22.4330, with a volume of 1,292,918 shares traded.</p>
<div class="lb-trans"><p>Arcus Biosciences, Inc. (NYSE:RCUS - 獲取免費報告) 的股票在週二交易前出現了跳空上漲。該股票之前收盤價為 21.30 美元，但開盤價為 22.19 美元。Arcus Biosciences 的股票最後交易價格為 22.4330 美元，成交量為 1,292,918 股。</p>
</div><p>Get <strong>Arcus Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Arcus Biosciences</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><ul>
<li>From laggards to leaders: Small caps on the rise</li>
</ul>
<div class="lb-trans"><ul>
<li>從滯後者到領頭羊：小型股正在崛起</li>
</ul>
</div><p>RCUS has been the subject of a number of recent research reports. Truist Financial set a $30.00 price objective on shares of Arcus Biosciences in a research note on Friday, December 12th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Arcus Biosciences in a research report on Wednesday, October 8th. Wells Fargo &amp; Company raised their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, October 20th. Morgan Stanley reiterated an &#34;equal weight&#34; rating and issued a $20.00 target price (down from $23.00) on shares of Arcus Biosciences in a report on Thursday, January 8th. Finally, The Goldman Sachs Group upgraded shares of Arcus Biosciences from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and raised their price target for the company from $16.00 to $28.00 in a report on Monday. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Arcus Biosciences currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $30.00.</p>
<div class="lb-trans"><p>RCUS 最近成為多份研究報告的主題。Truist Financial 在 12 月 12 日的研究報告中將 Arcus Biosciences 的股票目標價設定為 30.00 美元。Weiss Ratings 在 10 月 8 日的研究報告中重新發布了對 Arcus Biosciences 的 “賣出（d-）” 評級。Wells Fargo &amp; Company 在 10 月 20 日的研究報告中將 Arcus Biosciences 的目標價從 25.00 美元上調至 29.00 美元，並給予該公司 “增持” 評級。摩根士丹利在 1 月 8 日的報告中重申了 “持平” 評級，並將 Arcus Biosciences 的目標價設定為 20.00 美元（從 23.00 美元下調）。最後，高盛集團在週一將 Arcus Biosciences 的評級從 “中性” 上調至 “買入”，並將該公司的目標價從 16.00 美元上調至 28.00 美元。八位股票研究分析師對該股票給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Arcus Biosciences 目前的共識評級為 “適度買入”，平均目標價為 30.00 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on RCUS</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 RCUS 的最新股票分析</strong></p>
</div><h2>Arcus Biosciences Stock Up 4.8%</h2>
<div class="lb-trans"><h2>Arcus Biosciences 股票上漲 4.8%</h2>
</div><ul>
<li>MarketBeat Week in Review – 7/10 - 7/14</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 7/10 - 7/14</li>
</ul>
</div><p>The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of -6.49 and a beta of 0.77. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 3.65. The business has a fifty day moving average price of $22.62 and a two-hundred day moving average price of $15.72.</p>
<div class="lb-trans"><p>該公司的市值為 24.1 億美元，市盈率為-6.49，貝塔值為 0.77。公司的債務與股本比率為 0.22，流動比率為 3.65，速動比率為 3.65。該業務的 50 日移動平均價格為 22.62 美元，200 日移動平均價格為 15.72 美元。</p>
</div><p>Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its earnings results on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, beating analysts' consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The firm had revenue of $26.00 million for the quarter, compared to analyst estimates of $19.89 million. During the same quarter in the prior year, the firm earned ($1.00) earnings per share. Arcus Biosciences's revenue for the quarter was down 45.8% on a year-over-year basis. On average, equities analysts expect that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.</p>
<div class="lb-trans"><p>Arcus Biosciences (NYSE:RCUS - 獲取免費報告) 最近於 10 月 28 日發佈了其財報。該公司報告本季度每股收益為 (-1.27) 美元，超出分析師共識預期的 (-1.33) 美元 0.06 美元。Arcus Biosciences 的股本回報率為-68.17%，淨利潤率為-136.40%。該公司本季度的收入為 2600 萬美元，而分析師預期為 1989 萬美元。在去年同期，該公司每股收益為 (-1.00) 美元。Arcus Biosciences 本季度的收入同比下降了 45.8%。平均而言，股票分析師預計 Arcus Biosciences, Inc.在本年度將發佈每股收益為-3.15 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><ul>
<li>Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus</li>
</ul>
<div class="lb-trans"><ul>
<li>吉利德通過在 AlloVir 和 Arcus 的股份擴大生物技術足跡</li>
</ul>
</div><p>In related news, CEO Terry J. Rosen sold 28,947 shares of the business's stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $21.88, for a total transaction of $633,360.36. Following the completion of the transaction, the chief executive officer directly owned 2,220,553 shares in the company, valued at $48,585,699.64. The trade was a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jennifer Jarrett sold 11,225 shares of the company's stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $21.88, for a total transaction of $245,603.00. Following the completion of the sale, the chief operating officer directly owned 203,007 shares in the company, valued at approximately $4,441,793.16. The trade was a 5.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 422,060 shares of company stock valued at $9,286,202 over the last 90 days. Insiders own 9.60% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席執行官 Terry J. Rosen 於 12 月 16 日星期二出售了 28,947 股公司的股票。股票以平均價格 21.88 美元出售，總交易額為 633,360.36 美元。交易完成後，首席執行官直接持有公司 2,220,553 股，價值 48,585,699.64 美元。此次交易使其持股比例減少了 1.29%。該交易在向 SEC 提交的文件中披露，文件可在此鏈接查看。此外，首席運營官 Jennifer Jarrett 於 12 月 16 日星期二出售了 11,225 股公司的股票。股票以平均價格 21.88 美元出售，總交易額為 245,603.00 美元。交易完成後，首席運營官直接持有公司 203,007 股，價值約 4,441,793.16 美元。此次交易使其持股比例減少了 5.24%。該銷售的 SEC 文件提供了更多信息。在過去 90 天內，內部人士共出售了 422,060 股公司股票，價值 9,286,202 美元。內部人士持有公司股票的比例為 9.60%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its position in shares of Arcus Biosciences by 59.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company's stock worth $37,000 after buying an additional 1,021 shares during the last quarter. SBI Securities Co. Ltd. raised its stake in Arcus Biosciences by 13,547.6% during the 3rd quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company's stock worth $39,000 after acquiring an additional 2,845 shares in the last quarter. Abich Financial Wealth Management LLC purchased a new stake in Arcus Biosciences in the third quarter valued at $69,000. CWM LLC lifted its position in Arcus Biosciences by 233.6% in the second quarter. CWM LLC now owns 5,441 shares of the company's stock valued at $44,000 after acquiring an additional 3,810 shares during the last quarter. Finally, Ameritas Investment Partners Inc. boosted its stake in Arcus Biosciences by 34.3% in the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company's stock valued at $57,000 after acquiring an additional 1,796 shares in the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>機構投資者最近買賣了該股票的股份。GAMMA Investing LLC 在第三季度將其在 Arcus Biosciences 的股份增加了 59.1%。GAMMA Investing LLC 目前擁有 2,748 股公司股票，價值 37,000 美元，此前在上個季度又購買了 1,021 股。SBI Securities Co. Ltd.在第三季度將其在 Arcus Biosciences 的股份增加了 13,547.6%。SBI Securities Co. Ltd.目前擁有 2,866 股公司股票，價值 39,000 美元，此前在上個季度又收購了 2,845 股。Abich Financial Wealth Management LLC 在第三季度購買了 Arcus Biosciences 的新股份，價值 69,000 美元。CWM LLC 在第二季度將其在 Arcus Biosciences 的股份增加了 233.6%。CWM LLC 目前擁有 5,441 股公司股票，價值 44,000 美元，此前在上個季度又收購了 3,810 股。最後，Ameritas Investment Partners Inc.在第二季度將其在 Arcus Biosciences 的股份增加了 34.3%。Ameritas Investment Partners Inc.目前擁有 7,038 股公司股票，價值 57,000 美元，此前在上個季度又收購了 1,796 股。92.89% 的股票目前由對沖基金和其他機構投資者持有。</p>
</div><h2>Arcus Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Arcus Biosciences 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company's research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.</p>
<div class="lb-trans"><p>Arcus Biosciences 是一家臨牀階段的生物製藥公司，專注於新型癌症免疫療法的發現、開發和商業化。該公司的研究平台集中在通過小分子和抗體候選藥物調節腫瘤微環境和免疫檢查點。Arcus 旨在通過靶向腺苷軸和免疫細胞上的抑制受體等途徑增強抗腫瘤免疫反應。</p>
</div><p>The company's lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.</p>
<div class="lb-trans"><p>該公司的主要臨牀項目包括 etrumadenant，一種口服給藥的 A2A 腺苷受體拮抗劑，正在與抗 PD-1 療法聯合評估，以及 domvanalimab，一種抗 TIGIT 單克隆抗體。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Arcus Biosciences</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Ticker Revealed: Pre-IPO Access to &#34;Next Elon Musk&#34; Company</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Arcus Biosciences</li>
<li>埃隆將 SpaceX 上市！$100 的首次公開募股機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地被激活</li>
<li>股票代碼揭曉：獲得 “下一個埃隆·馬斯克” 公司的首次公開募股機會</li>
<li>崩盤已經開始（大多數人還未察覺）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Arcus Biosciences Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 $1,000 在 Arcus Biosciences 嗎？</h2>
</div><p>Before you consider Arcus Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Arcus Biosciences 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 Arcus Biosciences 並不在名單上。</p>
</div><p>While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Arcus Biosciences 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Arcus Biosciences (NYSE:RCUS) 股價跳空上漲 - 事情的經過